Home
About Us
History & Overview
Management
Board of Directors
Medical and Scientific Advisory Board
Business Advisory Board
Corporate Presentation
Corporate Fact Sheet
Our Approach
Key Advantages
Pipeline
Targeted Diseases
Stroke
Chronic Cough
IPF
CKD
Investors
Media
Contact Us
Search
Presentations
Investors
Investors
Overview
News & Events
Overview
Press Releases
IR Calendar
Email Alerts
Company Info
Overview
Management Team
Presentations
Contacts
FAQ
Financial Info
Overview
Financial Results
Income Statement
Balance Sheet
Cash Flow
Annual General Meeting
Stock Data
CSE:AGN
OTCQB:AGNPF
XFRA:AGN0
SEDAR
Governance
Overview
Board of Directors
Board Committees
Governance Documents
October 30, 2022
Algernon Pharma - October 2022
October 26, 2022
Corporate Fact Sheet October 26, 2022
rss_feed
RSS
Email Alerts
Contacts
RSS News Feed
Close
Search for:
Search
Hit enter to search or ESC to close
Home
About Us
History & Overview
Management
Board of Directors
Medical and Scientific Advisory Board
Business Advisory Board
Corporate Presentation
Corporate Fact Sheet
Our Approach
Key Advantages
Pipeline
NP-120 (Ifenprodil)
AP-188 (DMT)
DMT- Stroke Program
DMT Background
Algernon’s DMT Research Plan
Pathway to Clinical Trials
Stroke Program Consultants
Manufacturing, CRO’s and IP
Targeted Diseases
Stroke
Chronic Cough
IPF
Investors & Media
News Releases
Investor Resources
CSE: AGN | OTCQB: AGNPF | XFRA: AGW0
Filings
FAQ
Investor Relations
Analyst Coverage
Annual Meeting Materials
Media
Upcoming Events
Contact Us